A treatment approach first tested in residential programs at Caron Treatment Centers is now available to consumers through telehealth. Quel Health announced on Sept. 8 that it has launched as a national telehealth company built around the use of GLP-1 receptor agonists for addiction, with care available in 41 states and Washington, D.C., and national coverage planned by the end of the year.
The gap between that offering and the regulatory record is what patients and families most need to understand. The FDA has not approved any GLP-1 medication for a substance use disorder, a point the company acknowledges in its launch announcement. As STAT reported, that means the drugs will be prescribed off-label.
